To Assess the Safety, Tolerability & Pharmacokinetics of INCB086550

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00750841` - Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours	Phase 1
Withdrawn	`NCT05419817` - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System	Phase 2
Completed	`NCT02828930` - A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)	Phase 1
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Terminated	`NCT03225105` - M3541 in Combination With Radiotherapy in Solid Tumors	Phase 1
Completed	`NCT03258515` - A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers	Phase 1
Completed	`NCT01497925` - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT01878890` - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.	Phase 1
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Active, not recruiting	`NCT03634982` - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors	Phase 1
Recruiting	`NCT04685226` - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Recruiting	`NCT06036121` - A Study of ADRX-0706 in Select Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03258151` - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed	`NCT01528046` - Metformin in Children With Relapsed or Refractory Solid Tumors	Phase 1
Recruiting	`NCT05325866` - A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression	Phase 1/Phase 2
Recruiting	`NCT04557449` - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Phase 1/Phase 2
Completed	`NCT02759640` - A Phase I Trial of HS-10241 in Solid Tumors	Phase 1
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Completed	`NCT02279433` - A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	Phase 1

NCT number	NCT04674748
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 1
Start date	February 3, 2021
Completion date	May 13, 2022

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms